60% of patients with neuroendocrine tumours, the cause of carcinoid syndrome diarrhoea, say that it severely impacts their quality of life and emotional health. The UK affiliate of Ipsen (Euronext: IPN; ADR: IPSEY) last month announced that Xermelo® (telotristat ethyl) has been recommended by the All Wales Medicines Strategy Group (AWMSG) for use within NHS Wales for the treatment of adult patients living with carcinoid syndrome (CS) diarrhoea. Telotristat ethyl, which is administered orally in combination with somatostatin analogue (SSA)…